Search alternatives:
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
nn decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
e mean » _ mean (Expand Search), a mean (Expand Search), i mean (Expand Search)
Showing 381 - 400 results of 107,009 for search '(( e mean decrease ) OR ( 5 ((((step decrease) OR (nn decrease))) OR (a decrease)) ))', query time: 1.36s Refine Results
  1. 381
    Long-term anti-nucleocapsid response by baseline patient characteristics.

    Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  2. 382
    Baseline patient characteristics across neutralizing monoclonal antibody trials.

    Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  3. 383
    Study Flow Diagram.

    Study Flow Diagram. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  4. 384
    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies.

    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  5. 385
    Antibody and antigen responses to Ensovibep vs placebo day 1–90.

    Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  6. 386
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  7. 387
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  8. 388
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  9. 389
    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90.

    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  10. 390
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  11. 391
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  12. 392
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  13. 393
    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments).

    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  14. 394
    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity.

    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  15. 395
    <i>Vps13</i> mutant flies show a decreased life span, age dependent impairment of locomotor function and neurodegeneration.

    <i>Vps13</i> mutant flies show a decreased life span, age dependent impairment of locomotor function and neurodegeneration. by Jan J. Vonk (3686662)

    Published 2017
    Save to List
    Saved in:
  16. 396
    Effects of A1AR expression on response to hypoxia at E9.5 and E12.5.

    Effects of A1AR expression on response to hypoxia at E9.5 and E12.5. by Daniela L. Buscariollo (140729)

    Published 2013
    “…In hypoxia, E9.5 A1AR +/− heart rates decreased then returned to baseline levels following recovery in room air (p<0.0001 and p<0.01, for t = 25 and t = 40 compared to t = 0, respectively). …”
    Save to List
    Saved in:
  17. 397
    Overview of the six original ACTIV-3/TICO trials.

    Overview of the six original ACTIV-3/TICO trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  18. 398
    TachypleginA treatment causes a decrease in the motor activity of the TgMyoA motor complex.

    TachypleginA treatment causes a decrease in the motor activity of the TgMyoA motor complex. by Aoife T. Heaslip (207534)

    Published 2010
    Save to List
    Saved in:
  19. 399
    <i>Syx5</i> suppression in human cells decreases copper accumulation but does not affect rate of turnover.

    <i>Syx5</i> suppression in human cells decreases copper accumulation but does not affect rate of turnover. by Melanie Norgate (234832)

    Published 2010
    Save to List
    Saved in:
  20. 400
    HA-MAD1 tumors have increased CIN and decreased p53.

    HA-MAD1 tumors have increased CIN and decreased p53. by Sarah E. Copeland (13951506)

    Published 2024
    Save to List
    Saved in:

Search Tools: